Efficacy News and Research

RSS

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.

31 Aug 2015

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

Ascletis today announced it received the approval from the Taiwan Food and Drug Administration (TFDA) to start phase II clinical trial for its all-oral interferon (IFN)-free regimen to treat chronic hepatitis C (CHC).

31 Aug 2015

Leadless cardiac pacemakers could overcome complications of conventional transvenous pacemakers

A leadless cardiac pacemaker showed "good safety and reliable function" during the initial six months of follow-up in the LEADLESS II study, investigators reported during a Hot Line presentation at the ESC congress 2015.

31 Aug 2015

ATTEMPT-CVD trial results show that ARBs may have better impact on CVD biomarkers

When it comes to treating high blood pressure, not all anti-hypertensive medications are equal, and results of the ATTEMPT-CVD trial suggest that telmisartan, an angiotensin II receptor blocker (ARB) might have benefits over non-ARB treatment.

31 Aug 2015

Brain tumor is not always the death sentence

Only half of brain cancers actually start in the brain. The rest - as in the case of former president Jimmy Carter - are metastatic tumors from cancer that originated elsewhere in the body.

29 Aug 2015

New ESC Guidelines on infective endocarditis support role of imaging in diagnosis

ESC Guidelines published today on infective endocarditis boost the role of imaging in diagnosis of this deadly disease.

29 Aug 2015

Doc Wayne Youth Services selected as winner of 2015 Robert Wood Johnson Foundation Sports Award

Doc Wayne Youth Services, a Mass.-based nonprofit that fuses sport and therapy to heal and strengthen youth, has been selected as a 2015 winner of the inaugural Robert Wood Johnson Foundation Sports Award. Other winners in this elite group include Tony Hawk Foundation and Chicago Fire Foundation. Doc Wayne Youth Services and the other winners will each receive a $5,000 award and will be honored at a Sept. 10, 2015 ceremony at RWJF headquarters in Princeton, N.J.

28 Aug 2015

FDA approves MagVenture MagVita TMS Therapy system for treatment of Major Depressive Disorder

On July 31, 2015 the US Food and Drug Administration cleared the MagVita TMS Therapy system for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

28 Aug 2015

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2015 and updates on its drug development programs.

28 Aug 2015

Continuous therapy improves multiple myeloma outcomes

Patients with newly diagnosed multiple myeloma receive significant progression-free and overall survival benefits from continuous treatment compared with fixed-duration therapy, suggests a pooled analysis.

27 Aug 2015

UiO researchers test new nasal spray device for treating mental illness

Researchers at the University of Oslo have tested a new device for delivering hormone treatments for mental illness through the nose. This method was found to deliver medicine to the brain with few side effects.

27 Aug 2015

Transplanting multi-layered sheet of liver cells into damaged liver improves function in test animals

Liver transplantation is currently the only established treatment for patients with end stage liver failure. However, this treatment is limited by the shortage of donors and the conditional integrity and suitability of the available organs. Transplanting donor hepatocytes (liver cells) into the liver as an alternative to liver transplantation also has drawbacks as the rate of survival of primary hepatocytes is limited and often severe complications can result from the transplantation procedure.

27 Aug 2015

Researchers find that 26% of senior oncology patients use complementary or alternative medicines

Alternative medicines are widely thought to be at least harmless and very often helpful for a wide range of discomforts and illnesses. However, although they're marketed as "natural," they often contain active ingredients that can react chemically and biologically with other therapies.

27 Aug 2015

Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

Platform therapeutic company Symic Biomedical, Inc. announced today that it has received a $1.5M Phase II SBIR grant from the National Institutes of Health to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures, a significant unmet clinical need in end stage renal disease (ESRD) patients undergoing hemodialysis.

27 Aug 2015

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.

26 Aug 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London.

26 Aug 2015

Elite CBD Remedy Tincture now available through Mary's Nutritionals

Elite Botanicals, the leading cultivator of CBD-rich hemp in Colorado, today announced that it's Elite CBD Remedy Tincture is now available through medical and recreational dispensaries in Colorado, as well as online through Mary's Nutritionals.

26 Aug 2015

Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

Clementia Pharmaceuticals, Inc. today announced the initiation of enrollment of children as young as 6 years old in the company's ongoing Phase 2 study of palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP).

26 Aug 2015

Chrono obtains second Fast Track SBIR grant award from NCI to support development of smoking cessation therapy

Chrono Therapeutics, a pioneer in digital drug therapy, today announced it has received a second Phase 1 and Phase 2 Fast Track Small Business Innovation Research (SBIR) grant award from the National Cancer Institute.

26 Aug 2015

First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

CSL Behring announced today that the first patient has been enrolled in its Phase II/III clinical study evaluating the pharmacokinetics (PK), efficacy, and safety of the company's recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) for on-demand treatment in patients with congenital hemophilia A or B who have developed an inhibitor to factor VIII or factor IX replacement therapy.

26 Aug 2015

Efficacy News and Research

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

Leadless cardiac pacemakers could overcome complications of conventional transvenous pacemakers

ATTEMPT-CVD trial results show that ARBs may have better impact on CVD biomarkers

Brain tumor is not always the death sentence

New ESC Guidelines on infective endocarditis support role of imaging in diagnosis

Doc Wayne Youth Services selected as winner of 2015 Robert Wood Johnson Foundation Sports Award

FDA approves MagVenture MagVita TMS Therapy system for treatment of Major Depressive Disorder

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Continuous therapy improves multiple myeloma outcomes

UiO researchers test new nasal spray device for treating mental illness

Transplanting multi-layered sheet of liver cells into damaged liver improves function in test animals

Researchers find that 26% of senior oncology patients use complementary or alternative medicines

Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Elite CBD Remedy Tincture now available through Mary's Nutritionals

Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

Chrono obtains second Fast Track SBIR grant award from NCI to support development of smoking cessation therapy

First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News